Compare Cytokinetics Inc (CYTK) vs Enphase Energy Inc (ENPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Enphase Energy Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.50B), while Enphase Energy Inc trades at $33.24 (market cap $4.43B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Enphase Energy Inc is more actively traded (3,388,482 versus 2,395,556). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Enphase Energy Inc for 72 Days on average.
| CYTK | ENPH | |
|---|---|---|
Market Cap | $8.50B | $4.43B |
Volume | 2,395,556 | 3,388,482 |
Sector | Health | Energy |
52-Week High | $87.26 | $72.33 |
52-Week Low | $54.76 | $26.12 |
Typical Hold Time | 19 Days | 72 Days |
Enterprise Value | $8.60B | $4.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
ENPH trades at $33.50, down 1.21% on the day, with a bearish technical signal and mixed earnings history. Revenue declined to $1.47B in 2025 from $2.3B in 2023, though net income margin improved to 11.68%. Recent news includes product approvals and manufacturing milestones for AI data centers, but the stock faces pressure from high borrowing costs impacting the solar sector. The company maintains solid liquidity with $1.62B in cash, but debt levels remain elevated.
The outlook is cautious; analyst consensus is a Buy with a $42.90 price target, but recent earnings misses and sector headwinds pose risks. Upside depends on execution in AI infrastructure and EV charging, while competition and interest rate sensitivity are key concerns. The stock offers potential for recovery if operational trends stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →
